Adc Therapeutics SA
Adc Therapeutics SA (ADCT) Implied Volatility Current
ADCT's 30 day implied volatility is 0.01%, with an IV Rank of 5.56%. This is a low IV Rank versus the past year, meaning Adc Therapeutics SA options are relatively cheap and currently favor buyers. ADCT's 30 day historical volatility sits at 119.13%, which means implied volatility is running 119.12 points below historical volatility, as of Nov 16, 2026.
Read more
Tracking ADCT implied volatility helps you spot when Adc Therapeutics SA options are historically cheap or expensive, and where the best trades are hiding. When ADCT IV rises, premiums increase and sellers get more attractive pricing, and when it drops, buyers find cheaper contracts. Use our scanner to monitor ADCT implied volatility current levels in real time and filter for high probability trades.
Implied volatility is derived from option prices and represents the annualized expected move of a stock. Tracking ADCT IV rank helps you see whether ADCT's implied volatility is historically high or low, since IV rank compares today's reading against the past year's range. A high rank signals relatively expensive premiums and tends to favor sellers, a low rank signals relatively cheap premiums and tends to favor buyers.
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL in second-line transplant-ineligible patients; and Phase I clinical trial for treatment of relapsed or refractory non-hodgkin lymphoma (NHL). The company is also developing camidanlumab tesirine, an ADC that has completed Phase I clinical trial to treat relapsed or refractory NHL; in Phase II clinical trial in relapsed or refractory hodgkin lymphoma; and in Phase Ib clinical trial for selected advanced solid tumors.
Implied Volatility
IV is subdued. Premiums are cheap, favoring buyers.
As of Nov 16, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →